BioNexus Gene Ownership
| BGLC Stock | USD 6.43 0.39 5.72% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 1.8 M | Current Value 1.8 M | Avarage Shares Outstanding 8.6 M | Quarterly Volatility 31.1 M |
BioNexus Stock Ownership Analysis
About 51.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNexus Gene Lab has Price/Earnings (P/E) ratio of 350.0. The entity recorded a loss per share of 1.19. The firm had not issued any dividends in recent years. BioNexus Gene had 1:10 split on the 7th of April 2025. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people. For more info on BioNexus Gene Lab please contact SuLeng Tan at 60 1 307 241 6898 or go to https://www.bionexusgenelab.com.Besides selling stocks to institutional investors, BioNexus Gene also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different BioNexus Gene's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align BioNexus Gene's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
BioNexus Gene Quarterly Liabilities And Stockholders Equity |
|
About 51.0% of BioNexus Gene Lab are currently held by insiders. Unlike BioNexus Gene's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against BioNexus Gene's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of BioNexus Gene's insider trades
BioNexus Gene Lab Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioNexus Gene insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioNexus Gene's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioNexus Gene insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wei Leong over a year ago BioNexus Gene exotic insider transaction detected |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| VREX | Varex Imaging Corp | |
| ENPH | Enphase Energy | |
| BDC | Belden Inc |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.19) | Revenue Per Share 5.178 | Quarterly Revenue Growth (0.10) | Return On Assets (0.14) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.